期刊文献+

预防HIV感染的生物医学技术研究领域的投资趋势 被引量:3

Trends in Investment for Research and Development of HIV Biomedical Prevention Strategies
下载PDF
导出
摘要 监测、跟踪和分析HIV疫苗和杀微生物剂资源跟踪工作组2009年7月发布的最新研究资讯显示,在预防HIV感染的生物医学技术领域投资中,HIV疫苗研究最受重视,其次是杀微生物剂,再次是HIV暴露前预防。该领域最主要的投资者是美国政府和比尔与梅琳达盖茨基金;在HIV疫苗研究中,美国政府2008年显著地增加了疫苗开发前的基础研究经费投入,同时急剧削减了临床前研究的经费。在HIV疫苗上市还比较遥远的背景下,杀微生物剂研究的投入经费呈上升趋势,国际社会对以现有的抗逆转录病毒药物为基础的候选杀微生物剂的研究兴趣增加。HIV暴露前预防研究的经费投入呈上升趋势,被测试的药物是精选的抗逆转录病毒药物,通过Ⅲ期临床研究的可能性较大,该类药物的新用途具有商业潜力。
出处 《中国医药工业杂志》 CAS CSCD 北大核心 2010年第1期64-69,共6页 Chinese Journal of Pharmaceuticals
基金 国家科技重大专项(2008ZX10001-015) 广东高校优秀青年创新人才培育项目(艾滋病疫苗技术预见)
  • 相关文献

参考文献20

  • 1HIV Vaccines and Microbicides Resource Tracking Working Group. Adapting to realities: trends in HIV prevention research funding 2000 to 2008[~EB/OL]. (2009-07-23) [2009-07-20] http://www.hivresourcetracking, org/ downloads/adapting_torealities rt report.july09.pdf.
  • 2Fauci AS. 25 Years ofHIV [J]. Nature, 2008, 453: 289-290.
  • 3Fauci AS, Johnston MI, Dieffenbach CW, et al. HIV vaccine research: the way forward [J]. Science, 2008, 321 (5888) : 530-532.
  • 4Gandhi RT, O'Neill D, Bosch RJ, et al. A randomized therapeutic vaccine trial of canarypox-HIV-pulsed dendritic ceils vs. canarypox-HIV alone in HIV-1-infected patients on antiretroviral therapy [J]. Vaccine, 2009, 27(43) : 6088-6094.
  • 5Lemiale F, Korokhov N. Lentiviral vectors for HIV disease prevention and treatment [J]. Vaccine, 2009, 27(26): 3443-3449.
  • 6张冬梅,曾忠铭,兰建萍.预防艾滋病和其他性传播疾病的杀微生物剂研究进展[J].中国新药与临床杂志,2006,25(8):629-632. 被引量:10
  • 7张冬梅,刘叔文,曾忠铭,曾忠禄.专利检索分析预防艾滋病和其他性传播疾病的杀微生物剂开发进展[J].中国医药工业杂志,2008,39(4):313-317. 被引量:4
  • 8张冬梅,刘叔文,曾忠铭,曾忠禄.预防艾滋病的杀微生物剂发展趋势研究:德尔菲法调查[J].中国医药工业杂志,2009,40(8):637-640. 被引量:3
  • 9刘叔文,李卫华,丁训诚,姜世勃.预防HIV性传播的杀微生物剂[J].中国计划生育学杂志,2008,16(5):317-320. 被引量:12
  • 10HIV Vaccines and Microbicides Resource Tracking Working Group. What is PrEP for HIV prevention? [EB/OL]. (2009-07-25) [2009-07-20] http://www. hivresourcetracking.org/treatments/prep.

二级参考文献82

  • 1张冬梅,曾忠铭,兰建萍.预防艾滋病和其他性传播疾病的杀微生物剂研究进展[J].中国新药与临床杂志,2006,25(8):629-632. 被引量:10
  • 2Weiss HA, Halperin D, Bailey RC, et al. Male circumcision for HIV prevention : from evidence to action? AIDS, 2008, 22 (5) : 567-574.
  • 3WHO and UNAIDS announce recommendations from expert consultation on male circumcision for HIV prevention, http://www, who. int/hiv/mediacentre/news68/en/index, html.
  • 4WHO UNAIDS JHPIEGO. Manual for male circumcision under local anaesthesia. Version 2.5C, 2008. http://www, who. int/ hiv/pub/malecircumcision/local_anaesthesia/en/index, html.
  • 5WHO. Male circumcision quality assurance guide: a guide to enhancing the safety and quality of services. October 30, 2008. http ://www. who. int/hiv/pub/malecircumcision/qa_guide/en/index. html.
  • 6WHO and UNAIDS. Operational guidance for scaling up male circumcision services for HIV prevention. January, 2009. http://www, who. int/hiv/pub/malecircumcision/op_ guidance/ en/index, html.
  • 7WHO. Male circumcision: Quality assessment toolkit. January, 2009. http ://www. who. int/hiv/pub/malecircumcision/qa_toolkit/err/index, html.
  • 8Morris BJ. Why circumcision is a biomedical imperative for the 21(st) century. Bioessay, 2007, 29(11): 1147-1158.
  • 9Westerncamp N, Bailey RC. Acceptability of male circumcision for prevention of HIV/AIDS in Sub-Saharan Africa: a review. AIDS Behav, 2007, 11 (3) : 341-355.
  • 10Castellsague X, Bosch FX, Munoz N, et al., Male circumcision, penile human papillomavirus infection, and cervical cancer in female partners. N Engl J Med, 2002, 346( 15 ) : 1105-1112.

共引文献96

同被引文献23

  • 1张冬梅,曾忠铭,兰建萍.预防艾滋病和其他性传播疾病的杀微生物剂研究进展[J].中国新药与临床杂志,2006,25(8):629-632. 被引量:10
  • 2FDA. FDA approves first drug Truvada for reducing the risk of sexually acquired HIV infection [EB/OL]. [2012-07-16]. http://www.fda.gov/NewsEvents/Newsroom/PressAnnounce- ments/ucm312210.htm.
  • 3Cohen MS, Chen YQ, McCauley M, et al. Prevention of HIV-1 infection with early antiretroviral therapy [J]. New EnglJMed, 2011, 365 (6): 493-505.
  • 4HIV vaccines and microbicides resource tracking working group. Investing to end the AIDS epidemic: A new era for HIV prevention research & development [EB/OL]. [2012-07-20]. http://www.hivresourcetracking.org.
  • 5International AIDS vaccine initiative. Database of vaccine candidates in clinical trials [EB/OL]. [2012-08-14], http:// www.iavireport.org/Trials-Database/Pages/default.aspx.
  • 6Fauci AS. 25 years ofHIV [J]. Nature, 2008, 453: 289-290.
  • 7Fanci AS, Johnston MI, Dieffenbach CW, et al. HIV vaccine research: the way forward [J]. Science, 2008, 321 (5888) : 530-532.
  • 8Gandhi RT, O'Neill D, Bosch RJ, et al. A randomized therapeutic vaccine trial of canarypox-HIV-pulsed dendritic cells vs. canarypox-HIV alone in HIV-l-infected patients on antiretroviral therapy [J]. Vaccine, 2009, 27 (43) : 6088-6094.
  • 9Korokhov N. Lentiviral vectors for HIV disease prevention and treatment [J]. Vaccine, 2009, 27 (26) : 3443-3449.
  • 10Kresge KJ. Balancing the AIDS vaccine budget [J]. 1AV1 Report, 2008, 12 (2) : 1, 8-9.

引证文献3

二级引证文献5

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部